DeepMed Research

Bimatoprost

Generic Name: Bimatoprost

Brand Names: Durysta, Latisse, Lumigan

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₇NO_₄

CAS Number: 155206-00-1

Unique Ingredient Identifier: QXS94885MZ

Background: Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.

Indication: Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.

Bimatoprost is also indicated to treat eyelash hypotrichosis.

Associated Conditions: Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP)

Clinical Trials

24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension

Phase 4

Completed

Conditions: Ocular Hypertension

Interventions: Drug: timolol-dorzolamide fixed combination
Drug: Latanoprost
Drug: Travoprost
Drug: 0.5% timolol
Drug: Bimatoprost

First Posted Date: 2012-08-02

Last Posted Date: 2012-08-02

Lead Sponsor: University of Parma

Target Recruit Count: 61

Registration Number: NCT01655758

Locations: 🇮🇹
University Eye Clinic, Parma, Italy

A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Completed

Conditions: Ocular Hypertension
Glaucoma, Open-Angle

Interventions: Drug: Bimatoprost

First Posted Date: 2012-07-20

Last Posted Date: 2014-06-13

Lead Sponsor: Allergan

Target Recruit Count: 2580

Registration Number: NCT01646151

A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: bimatoprost 0.01%

First Posted Date: 2012-07-03

Last Posted Date: 2012-09-21

Lead Sponsor: Allergan

Target Recruit Count: 10337

Registration Number: NCT01632423

Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: bimatoprost 0.01%

First Posted Date: 2012-06-27

Last Posted Date: 2012-09-24

Lead Sponsor: Allergan

Target Recruit Count: 854

Registration Number: NCT01628588

An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes

Completed

Conditions: Eyelash Hypotrichosis

Interventions: Drug: bimatoprost 0.03%

First Posted Date: 2012-06-20

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 585

Registration Number: NCT01623479

A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)

Phase 4

Completed

Conditions: Ocular Hypertension
Glaucoma, Open-Angle

Interventions: Drug: Bimatoprost 0.01%

First Posted Date: 2012-05-09

Last Posted Date: 2014-01-28

Lead Sponsor: Allergan

Target Recruit Count: 800

Registration Number: NCT01594970

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: bimatoprost 0.01% ophthalmic solution

First Posted Date: 2012-05-02

Last Posted Date: 2014-06-13

Lead Sponsor: Allergan

Target Recruit Count: 419

Registration Number: NCT01589510

Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost 0.01% ophthalmic solution

First Posted Date: 2012-04-02

Last Posted Date: 2013-09-20

Lead Sponsor: Allergan

Target Recruit Count: 933

Registration Number: NCT01568008

Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction

Phase 4

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: travoprost ophthalmic solution 0.004%
Drug: Bimatoprost ophthalmic solution 0.01%
Drug: travoprost 0.004% / timolol 0.5% combination ophthalmic solution

First Posted Date: 2012-03-08

Last Posted Date: 2014-08-15

Lead Sponsor: Allergan

Target Recruit Count: 135

Registration Number: NCT01547598

A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: 0.1% brimonidine tartrate ophthalmic solution
Drug: 0.01% bimatoprost ophthalmic solution
Drug: 0.2% hypromellose lubricant eye drops
Drug: latanoprost 0.005% ophthalmic solution

First Posted Date: 2012-02-02

Last Posted Date: 2013-12-04

Lead Sponsor: Allergan

Target Recruit Count: 137

Registration Number: NCT01525173

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy